In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ariad Pharmaceuticals Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.ariad.com

Latest From Ariad Pharmaceuticals Inc.

Ferring And Blackstone Launch Gene Therapy Company

The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.

Gene Therapy Strategy

Takeda: 12 NMEs Poised To Launch In Five Years, And Deliver $10 Bn In Peak Sales

The Japanese pharma held its first investor day in New York, outlining the company's strategy to deliver long-term growth through a newly energized oncology, gastrointestinal and rare disease pipeline.

Business Strategies Cancer

Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

Business Strategies Deals

BIO 2019 Notebook: Sharpless On Pricing, Marks On Gene Therapy, Takeda On M&A

News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates; and Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout.

Pricing Debate Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Paris Panayiotopoulos, Pres. & CEO
    Jennifer L Herron, EVP, Chief Commercial Officer
    Hugh M Cole, SVP & CBO
  • Contact Info
  • Ariad Pharmaceuticals Inc.
    Phone: (617) 494-0400
    26 Landsdowne St.
    Cambridge, MA 02139-4234
    USA
UsernamePublicRestriction

Register